Oncology and Hematology News and Journal Articles
Cancer Network presents exclusive coverage from the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2015. Below we bring you reports of the latest research, trials, scientific advances, and controversies that are changing the way gastrointestinal cancers are managed and treated.
Adding bevacizumab to paclitaxel did not improve outcomes in a phase II trial of patients with angiosarcoma.
Daratumumab, a monoclonal antibody that targets CD38, was safe and effective in patients with heavily pretreated and refractory multiple myeloma.
Tracking tumor DNA in the blood of early breast cancer patients following surgery predicted relapse nearly 8 months earlier than conventional imaging.
In this interview with Dr. Roy S. Herbst, we discuss the FDA approval of nivolumab for lung cancer as well as other immunotherapies under investigation for the treatment of lung cancer.
Beta-blockers were associated with increased overall survival in women with epithelial ovarian cancer, according to a retrospective study.
In this video, Dr. Paz-Ares discusses a phase III study that showed that nivolumab improved survival and response rates in previously treated patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
In this video, Steven I. Sherman, MD, discusses the final overall survival analysis of the EXAM study, a randomized, placebo-controlled phase III trial of cabozantinib in medullary thyroid carcinoma patients.
In this video, Dr. El-Khoueiry discusses results from a phase I/II study that suggest the PD-1 inhibitor nivolumab is safe and effective in advanced hepatocellular carcinoma.
In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma.
This slide show on anaplastic thyroid carcinoma features images of cellular pleomorphism, large atypical cells, myxoid degeneration, and bizarre giant cells.